Latest Health News

Holista Colltech has partnered with Swang Chai Chuan to develop a nano-collagen production facility in Western Australia, marking a major step in commercialising its collagen technology with a $1.6 million initial investment.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

GR Production Services secures a five-year $57 million operations and maintenance contract at the Sturt Plateau Compression Facility in the Northern Territory's Beetaloo Basin, with potential extension for three more years.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

Vertex Minerals accelerated gold production at its Reward Gold Mine to 284 ounces in the March quarter, supported by underground rehabilitation, operational upgrades, and new funding facilities. The company also expanded its exploration footprint with the Dun Dun licence and is pursuing 24/7 underground mining approval.

Freehill Mining’s aggregates business surged with a 59% jump in quarterly sales, while new copper project options promise to shift the company’s growth trajectory.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.